Anavex Life Sciences Corp (AVXL)

[Investor2014]

On a quick look you seem to have taken the worst case of the error bars from each of the data points (for all patients) as published by Anavex for the 57 week CTAD update.

You introduce additional error since we do not have the numbers in tabular form. The figures are hard to read accurately off the graph, say +/- .5 of a point.

Finally you have ignored considering the strong responder data on the CTAD slide no 30.
As far as I know, no such strong responders have been reported in any other AD trial so far.

The strong responders plus the upturn at 57 weeks is what interest me most when taken alongside the positive correlation of the other measures and 'unexpected therapeutic effects'.

We also know that dose were not optimised for the phase 2b trial and that there is evidence of correlation between does and effect.

As always we won't be certain of success until we see the results of the planned P2/3 trial.